Board members of Qlife subscribe for warrants

The subscription period in Qlife's directed issue of warrants to board members ended on May 17, 2021. Board members subscribed a total of 40,000 warrants for the price of SEK 6.11 per warrant.

At the Annual General Meeting on May 5, 2021, an incentive program aimed at three new board members of the company was resolved.  The warrant terms are based on a market valuation according to Black Scholes, based on the volume-weighted price May 6, 2021 through May 12, 2021. The terms mean that a warrant subscribed for at the price of SEK 6.11 can be redeemed against a new share with a strike price of SEK 67.08 during the period May 1, 2024 to May 31, 2024.

In addition to participating in the directed warrant program, board members have chosen to invest in the ongoing subscription of shares through exercise of TO1 warrants and directly in share purchases.

For further information, please contact:

Mette Gross, Chair Qlife Holding AB

E-mail: mette.gross@lehdab.com

Tel. No.: +46 (0)73-517 85 25

About Qlife

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.